

Avita Medical to Present at Needham Healthcare Conference

Valencia, CA, USA, Perth, Australia and London, United Kingdom, 23 March 2017 — Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, today announced that Adam Kelliher, Avita's Chief Executive Officer will present at the 16th Annual Needham Healthcare Conference on 4 April, 2017. The presentation will take place at 9:20am ET at The Westin Grand Central in New York City.

Mr. Kelliher's presentation will update audiences on Avita's commercial, regulatory, scientific and clinical research developments, providing recent data and outcomes across the range of indications for which the Company's portfolio of products (ReCell®, ReGenerCell™ and ReNovaCell™) are in use within various markets. Mr. Kelliher will also discuss Avita's contract award from the Biomedical Advanced Research and Development Authority (BARDA) to deploy ReCell® as a medical countermeasure for US mass casualty preparedness. A review of the FDA approval pathway and progress will also be provided.

Presentation details:

Date: Tuesday, 4 April, 2017
Time: 9:20am ET
Location: The Westin Grand Central in New York

###

ABOUT RECELL® AND RES™

ReCell® is Avita Medical's unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin, yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.

ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway. To learn more, visit www.avitamedical.com.

###

FOR FURTHER INFORMATION:

| | |
|---|--|
| <p>Avita Medical Ltd Adam Kelliher Chief Executive Officer Phone: +44 020 8947 9804 akelliher@avitamedical.com</p> <p>Avita Medical Ltd Tim Rooney Chief Financial Officer Phone: + 1 (661) 367-9170 trooney@avitamedical.com</p> | <p>Australia Monsoon Communications Sarah Kemter Phone: +61 (0)3 9620 3333 Mobile: +61 (0)407 162 530 sarahk@monsoon.com.au</p> <p>USA Westwicke Partners Jamar Ismail Phone +1 (415) 513-1282 jamar.ismail@westwicke.com</p> |
|---|--|